Published in

IOS Press, Journal of Alzheimer's Disease, 1(95), p. 339-348, 2023

DOI: 10.3233/jad-230159

Links

Tools

Export citation

Search in Google Scholar

Causal Effects of Plasma Haptoglobin Levels on Alzheimer’s Disease: A Two-Sample Mendelian Randomization Study

Journal article published in 2023 by Yijia Lin, Tingjun Hu, Lizhen Cheng, Yixin Chen, Wei Li, Qihao Guo, Ya Miao
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Background: A connection between plasma levels of haptoglobin (Hp) and Alzheimer’s disease (AD) has been shown in several observational studies. It is debatable, nonetheless, how the two are related causally. Objective: To establish the causal relationship between Hp and AD using a two-sample Mendelian randomization (MR) study. Methods: From the extensive genome-wide association studies and FinnGen dataset, summaries and statistics pertaining to AD were gathered. We investigated the possibility of a causal link between Hp and AD using a two-sample MR study. Inverse variance weighting was used as the primary analytical technique, and it was supported by the joint application of complementary analyses and fixed effects meta-analysis to combine results from various sources. Results: Genetically determined Hp was causally associated with AD [odds ratio (OR), 1.05; 95% confidence interval (CI), 1.02 to 1.09; p = 8.96×10–4]; Inverse variance-weighted estimates coming from different data sources were combined in a meta-analysis with consistent findings (OR, 1.03; 95% CI, 1.01 to 1.05; p = 2.00×10–3). The outcomes of the inverse MR analysis showed that AD had no appreciable causal impact on Hp. Conclusion: The present MR analysis shows that higher plasma Hp leads to an increased risk of AD. Strategies for plasma Hp testing may open up new doors for the early diagnosis and prevention of AD.